玫琳凯基金会向Baylor Scott & White捐款10万美元以支持三阴性乳腺癌研究
达拉斯 (美国商业资讯)–玫琳凯基金会(The Mary Kay FoundationSM)引领根除女性癌症的使命已有数十载,该基金会最近向Baylor Scott & White达拉斯基金会捐款10万美元,以资助TEXAS Oncology的乳腺癌医生、贝勒大学医疗中心乳腺癌研究“颂扬女性”(Celebrating Women)主任Joyce...
View Article玫琳凯基金会向癌症研究和家暴庇护所提供310万美元资助
达拉斯 (美国商业资讯)–玫琳凯基金会(The Mary Kay FoundationSM)最近向全美癌症研究和家庭暴力庇护所提供300多万美元资助。玫琳凯基金会创立于1996年,首要目的是消除那些影响女性的癌症。2000年,基金会将终止家庭暴力纳入其服务宗旨。...
View ArticleEpizyme Establishes Agreements for Up to $270 Million in Funding to Support...
CAMBRIDGE, Mass. Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced funding agreements with Royalty Pharma and its affiliate...
View ArticleHarbour BioMed Announces Initiation of First-in-human Study of...
CAMBRIDGE, Mass. & ROTTERDAM, The Netherlands & SHANGHAI Harbour BioMed (HBM) today announced the start of the first clinical trial of its next-generation fully human anti-CTLA-4 antibody...
View Article武田公布2019财年第二季度稳健业绩并上调全年利润指引
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502, NYSE:TAK): 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20191104006113/zh-CN/ 与2018财年上半年形式营收2...
View ArticleTakeda and MD Anderson Announce Collaboration to Accelerate the Development...
HOUSTON & OSAKA, Japan The University of Texas MD Anderson Cancer Center and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced an exclusive license agreement...
View ArticleCANbridge Receives Hong Kong Department of Health Market Approval for NERLYNX®
BEIJING CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, announced that it...
View ArticleSeattle Genetics and BeiGene Announce Global License Agreement for Advanced...
BOTHELL, Wash. & BEIJING & CAMBRIDGE, Mass. Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have entered into a license...
View ArticleOncternal Therapeutics Announces Interim Clinical Data on TK216 in Ewing...
SAN DIEGO Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim data on TK216 –...
View Articleメアリー・ケイ財団、がん研究と家庭内暴力シェルター助成金として310万ドルを授与
ダラス (ビジネスワイヤ) — メアリー・ケイ財団は先ごろ、米国内のがん研究と家庭内暴力シェルター助成金へ300万ドル以上を授与しました。メアリー・ケイ財団は、女性に影響を与えるがんの撲滅を全体的な目的として1996年に設立されました。2000年に財団は活動を広げ、その使命の一つに家庭内暴力の終焉を含めました。...
View ArticlePromega Enters Global Collaboration with Merck to Develop Microsatellite...
MADISON, Wis. Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite...
View ArticleTakeda to Highlight Expanded Portfolio of Products Across Oncology and...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that it will present a total of 29 company-sponsored abstracts at the 61st American...
View Article路胜生物与迈杰(苏州)在中国合作开发领先的癌症检测
苏州 新加坡领先的基因组医学公司路胜生物苏州有限公司(简称路胜)宣布将与迈杰转化医学研究(苏州)有限公司 【简称(迈杰(苏州)】建立战略合作伙伴关系,共同开发癌症检测,包括伴随诊断,这一举动不仅造福广大癌症患者,而且为新药研发公司提供更多的创新合作机会。 本新闻稿包含多媒体。此处查看新闻稿全文:...
View ArticleMEDx (Suzhou) and Lucence Partner to Co-Develop Cutting-Edge Cancer-Care Tests
SUZHOU, China MEDx (Suzhou) Translational Medicine, and Singapore-based Lucence – a leading genomic medicine company – today announced an agreement to pursue a strategic partnership in China to...
View ArticleTeva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs)...
JERUSALEM & PARSIPPANY, N.J. & INCHEON, South Korea Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Celltrion, Inc., (KRX...
View Articleプロメガがキイトルーダと共用するためのマイクロサテライト不安定性(MSI)コンパニオン診断薬の開発でメルクと世界規模の協業に入る
米ウィスコンシン州マディソン (ビジネスワイヤ) —...
View ArticlePhase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of...
View ArticleSouth Korean Company, Yuhan Pharmaceuticals Partners with Cyclica to Advance...
TORONTO & SEOUL, South Korea Renowned South Korean healthcare company, Yuhan Pharmaceuticals (Yuhan) and Cyclica Inc. (Cyclica), a leading neo biotechnology company announce a collaboration to...
View Article武田和MD安德森宣布合作以加快开发临床阶段、开箱即用型CAR NK细胞治疗平台
休斯敦和日本大阪 (美国商业资讯)–德克萨斯大学MD安德森癌症中心(The University of Texas MD Anderson Cancer Center)和武田药品工业株式会社(Takeda Pharmaceutical Company Limited,...
View Article